NCT00562224已完成1 期
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 4
- 主要终点
- Dose limiting toxicity assessment at the end of the first 28 day cycle.
研究概览
简要总结
To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age ≥ 18 years
- •Histologically confirmed, measurable solid tumor, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, or multiple myeloma that has relapsed after standard therapy or for which no standard therapy exists
- •Ability to swallow oral capsules without difficulty
- •Estimated life expectancy > 12 weeks
- •ECOG performance status ≤ 2
- •Creatinine ≤ 1.5 × institutional upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5 × institutional ULN (unless elevated from documented Gilbert's syndrome)
- •AST and ALT ≤ 2.5 × institutional ULN (≤ 5 × institutional ULN in the presence of liver metastases)
- •Platelet count ≥ 100,000/µL
- •ANC ≥ 1500/µL
- •Hgb ≥ 9.0 g/dL
- •Patients with previously treated, stable, asymptomatic brain metastases who are not on corticosteroids are eligible
- •Willing and able to sign a written informed consent-
排除标准
- •Patients who have had immunotherapy, chemotherapy, or radiotherapy within 4 weeks (within 6 weeks for nitrosoureas or mitomycin C) prior to first day of drug dosing
- •Patients who have undergone major surgery within 4 weeks prior to first day of drug dosing
- •Patients who have received another investigational drug within 4 weeks
- •Evidence of leptomeningeal metastasis
- •Patients unable to swallow oral medications or with pre-existing gastrointestinal disorders that might interfere with proper absorption of the oral drugs (eg, WDHA syndrome, carcinoid syndromes, diarrhea due to infections, malabsorption syndromes secondary to surgery or chemotherapy)
- •Uncontrolled illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that would limit compliance with study requirements
- •Patients with risk factors for, or who are receiving medications known to prolong QTc interval and that may be associated with Torsades de Pointes
- •QTc prolongation (defined as a QTc interval ≥ 450 msecs) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min).
- •History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stenting within the past 6 months.
- •Patients with known HIV infection
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
研究组 & 干预措施
Arm 1
Experimental
All study subjects will receive PCI-24781 (study drug).
干预措施: PCI-24781 (Drug)
结局指标
主要结局
Dose limiting toxicity assessment at the end of the first 28 day cycle.
时间窗: at the end of the first 28 day cycle
次要结局
- Measure: Adverse event assessed through 30 days after last dose of study drug Measure: Tumor response Measure: Pharmacokinetic/Pharmacodynamic assessments(AE through 30 days after last dose of study drug, Tumor response at the end of every 2nd 28 day cycle, PK/PD assessments on Day 1, 2, 3 (or 4 or 5), and Day 8 of cycle 1)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.Refractory or Recurrent CD30+ Hematologic MalignanciesNCT03894150Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.45
已完成
1 期
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)Solid TumorsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic. B-CellMultiple MyelomaNCT00871663Merck Sharp & Dohme LLC123
已完成
1 期
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEpithelial Ovarian CancerNCT02480374Imunon18
终止
1 期
Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory CancerNeoplasmsNCT00547261Sanofi6
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36